Market closedADR

Compass Pathways/$CMPS

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Compass Pathways

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Ticker

$CMPS
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
London, United Kingdom

Employees

186
Website
compasspathways.com

Compass Pathways Metrics

BasicAdvanced
$231M
-
-$2.19
2.30
-

$231M

2.3

$12.75

$3.17

918K

8.915

7.896

14.556

16.864

-34.43%

-35.22%

-64.68%

1.19

1.19

-2.106

-13.29%

9.24%

What the Analysts think about Compass Pathways

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Compass Pathways stock.

Compass Pathways Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Compass Pathways Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Compass Pathways News

AllArticlesVideos
Compass Pathways Announces Pricing of Underwritten Offering

Compass Pathways Announces Pricing of Underwritten Offering

Business Wire·5 days ago
Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)

Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)

Business Wire·4 weeks ago
Compass Pathways to Participate in December Investor Conferences

Compass Pathways to Participate in December Investor Conferences

Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CMPS

$

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Compass Pathways stock?

Compass Pathways (CMPS) has a market cap of $231M as of January 15, 2025.

What is the P/E ratio for Compass Pathways stock?

The price to earnings (P/E) ratio for Compass Pathways (CMPS) stock is 0 as of January 15, 2025.

Does Compass Pathways stock pay dividends?

No, Compass Pathways (CMPS) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Compass Pathways dividend payment date?

Compass Pathways (CMPS) stock does not pay dividends to its shareholders.

What is the beta indicator for Compass Pathways?

Compass Pathways (CMPS) has a beta rating of 2.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.